CY1115078T1 - Παραγωγα πυραζολοαμινοπυριδινης χρησιμα ως αναστολεις της κινασης - Google Patents

Παραγωγα πυραζολοαμινοπυριδινης χρησιμα ως αναστολεις της κινασης

Info

Publication number
CY1115078T1
CY1115078T1 CY20121100025T CY121100025T CY1115078T1 CY 1115078 T1 CY1115078 T1 CY 1115078T1 CY 20121100025 T CY20121100025 T CY 20121100025T CY 121100025 T CY121100025 T CY 121100025T CY 1115078 T1 CY1115078 T1 CY 1115078T1
Authority
CY
Cyprus
Prior art keywords
pyrazoloaminpyridine
producers
models
useful
novel
Prior art date
Application number
CY20121100025T
Other languages
English (en)
Inventor
Audrey Davies
Michelle Lamb
Paul Lyne
Peter Mohr
Bin Wang
Tao Wang
Dingwei Yu
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1115078T1 publication Critical patent/CY1115078T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Η εφεύρεση αυτή αφορά νεοφανείς χημικές ενώσεις που εμπεριέχονται στον Τύπο (Ι) τις φαρμακευτικές τους συνθέσεις και τις μεθόδους χρήσης τους. Αυτές οι νεοφανείς χημικές ενώσεις παρέχουν θεραπεία για τον καρκίνο.
CY20121100025T 2005-02-04 2012-01-11 Παραγωγα πυραζολοαμινοπυριδινης χρησιμα ως αναστολεις της κινασης CY1115078T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US65005305P 2005-02-04 2005-02-04
US65332905P 2005-02-16 2005-02-16
US72163305P 2005-09-29 2005-09-29
EP06701619A EP1846394B1 (en) 2005-02-04 2006-02-01 Pyrazolylaminopyridine derivatives useful as kinase inhibitors

Publications (1)

Publication Number Publication Date
CY1115078T1 true CY1115078T1 (el) 2016-12-14

Family

ID=36177856

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20121100025T CY1115078T1 (el) 2005-02-04 2012-01-11 Παραγωγα πυραζολοαμινοπυριδινης χρησιμα ως αναστολεις της κινασης
CY20151101071T CY1119077T1 (el) 2005-02-04 2015-11-26 Παραγωγα πυραζολυλαμινοπυριδινης χρησιμα ως αναστολεις κινασων

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20151101071T CY1119077T1 (el) 2005-02-04 2015-11-26 Παραγωγα πυραζολυλαμινοπυριδινης χρησιμα ως αναστολεις κινασων

Country Status (30)

Country Link
US (2) US8324252B2 (el)
EP (2) EP2383268B1 (el)
JP (1) JP5139084B2 (el)
KR (1) KR101302945B1 (el)
CN (1) CN101155800B (el)
AR (1) AR056184A1 (el)
AT (1) ATE530545T1 (el)
AU (1) AU2006210710B2 (el)
BR (1) BRPI0606793A8 (el)
CA (1) CA2595834C (el)
CY (2) CY1115078T1 (el)
DK (2) DK2383268T3 (el)
ES (2) ES2555063T3 (el)
HK (2) HK1114374A1 (el)
HR (1) HRP20110962T1 (el)
HU (1) HUE025671T2 (el)
IL (1) IL184674A (el)
ME (1) ME02645B (el)
MX (1) MX2007009437A (el)
MY (1) MY149512A (el)
NO (1) NO341112B1 (el)
NZ (1) NZ561145A (el)
PL (2) PL1846394T3 (el)
PT (2) PT1846394E (el)
RS (1) RS52061B (el)
SA (1) SA06270007B1 (el)
SI (2) SI2383268T1 (el)
TW (1) TWI370127B (el)
UY (1) UY29360A1 (el)
WO (1) WO2006082392A1 (el)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1853588T1 (sl) 2005-02-16 2008-10-31 Astrazeneca Ab Kemične spojine
EP1899323A2 (en) * 2005-05-16 2008-03-19 AstraZeneca AB Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
BRPI0618011A2 (pt) 2005-10-28 2011-08-16 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente
EP2083624A4 (en) * 2006-10-18 2010-06-16 Merck Sharp & Dohme 2-HYDROXY-2-PHENYL / THIOPHENYLPROPIONAMIDE AS ANDROGEN RECEPTOR MODULATORS
WO2008053812A1 (fr) * 2006-10-27 2008-05-08 Mitsubishi Tanabe Pharma Corporation Dérivé de cyanopyridine et son utilisation médicale
TW200826937A (en) * 2006-11-01 2008-07-01 Astrazeneca Ab New use
WO2008117050A1 (en) * 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
UA99459C2 (en) * 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
JP5524491B2 (ja) * 2008-03-04 2014-06-18 石原産業株式会社 ３−アミノ−２−クロロ−６−トリフルオロメチルピリジンの製造方法
TW201011017A (en) * 2008-08-19 2010-03-16 Astrazeneca Ab Chemical compounds 495-1
EP2338888A1 (en) 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
MX2012015023A (es) * 2010-06-30 2013-04-03 Fujifilm Corp Derivado novedoso de nicotinamida o sal del mismo.
UY33517A (es) 2010-07-19 2012-02-29 Astrazeneca Ab Depósito farmacéutico para 5-fluoro-2-[[(1S)-1-(5-fluoro-2-piridil)etil]amino]-6-[(5-isopropoxi-1H-pirazol-3-il)amino]piridin-3-carbonitrilo?.
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
TWI546287B (zh) 2011-12-28 2016-08-21 富士軟片股份有限公司 新穎菸鹼醯胺衍生物或其鹽
US9365556B2 (en) 2012-03-16 2016-06-14 Axikin Pharmaceuticals, Inc. 3,5-diaminopyrazole kinase inhibitors
TWI585088B (zh) 2012-06-04 2017-06-01 第一三共股份有限公司 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物
EP3369730B1 (en) * 2012-11-05 2020-08-05 Emory University 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
HRP20220738T1 (hr) 2014-08-11 2022-08-19 Acerta Pharma B.V. Terapijske kombinacije inhibitora btk, inhibitora pd-1 i/ili inhibitora pd-l1
EP3179991B1 (en) 2014-08-11 2021-10-06 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor
MY191736A (en) 2014-12-23 2022-07-13 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
CN109071444A (zh) 2016-03-16 2018-12-21 拜耳作物科学股份公司 作为农药和植物保护剂的n-(氰苄基)-6-(环丙基-羰基氨基)-4-(苯基)-吡啶-2-羧酰胺衍生物及相关化合物
US20220235013A1 (en) 2017-03-21 2022-07-28 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
CA3097231A1 (en) 2018-04-18 2019-10-24 Bayer Pharma Aktiengesellschaft 2-methyl-aza-quinazolines
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
JP7318009B2 (ja) 2019-05-21 2023-07-31 浙江海正薬業股▲ふん▼有限公司 マクロライド誘導体、その製造方法および用途
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
US6200977B1 (en) 1998-02-17 2001-03-13 Tularik Inc. Pyrimidine derivatives
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
DE19917785A1 (de) 1999-04-20 2000-10-26 Bayer Ag 2,4-Diamino-pyrimidin-Derivate
US6399780B1 (en) 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
DE60023926T2 (de) 1999-09-10 2006-07-20 Merck & Co., Inc. Tyrosin kinase inhibitoren
JP4794793B2 (ja) 1999-12-28 2011-10-19 ファーマコペイア， インコーポレイテッド Ｎ−ヘテロ環ＴＮＦ−α発現阻害剤
CN1429222A (zh) 2000-02-17 2003-07-09 安姆根有限公司 激酶抑制剂
ES2559273T3 (es) 2000-05-08 2016-02-11 Janssen Pharmaceutica Nv Profármacos de pirimidinas que inhiben la replicación del VIH
CA2406979A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
PL360742A1 (en) 2000-08-31 2004-09-20 Pfizer Products Inc. Pyrazole derivatives and their use as protein kinase inhibitors
EP1317446A1 (en) 2000-09-01 2003-06-11 Glaxo Group Limited Oxindole derivatives
JP2004517049A (ja) 2000-09-01 2004-06-10 グラクソ　グループ　リミテッド チロシンキナーゼ阻害剤としての置換オキシインドール誘導体
AU2001292670A1 (en) * 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
MXPA03005606A (es) 2000-12-21 2003-10-06 Vertex Pharma Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
DK1347971T3 (da) 2000-12-21 2006-05-15 Bristol Myers Squibb Co Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien
US20030130264A1 (en) 2001-02-16 2003-07-10 Tularik Inc. Methods of using pyrimidine-based antiviral agents
ATE343575T1 (de) 2001-09-27 2006-11-15 Smithkline Beecham Corp Azaoxoindol derivate als trk protein kinase hemmstoffe zur behandlung von krebs und chronischem schmerz
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
JP2003231687A (ja) 2002-02-04 2003-08-19 Japan Tobacco Inc ピラゾリル縮合環化合物及びその医薬用途
AU2003286711A1 (en) 2002-10-25 2004-05-13 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
ES2421139T3 (es) 2003-07-30 2013-08-29 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para su uso en el tratamiento o la prevención de enfermedades autoinmunitarias
MY141220A (en) * 2003-11-17 2010-03-31 Astrazeneca Ab Pyrazole derivatives as inhibitors of receptor tyrosine kinases
JP2007533717A (ja) * 2004-04-21 2007-11-22 アストラゼネカ アクチボラグ 化合物
EP1794135A1 (en) 2004-09-27 2007-06-13 Amgen Inc. Substituted heterocyclic compounds and methods of use
EP1831216A2 (en) 2004-12-23 2007-09-12 Pfizer Products Inc. Heteroaromatic derivatives useful as anticancer agents
ATE519759T1 (de) 2004-12-30 2011-08-15 Exelixis Inc Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren
SI1853588T1 (sl) 2005-02-16 2008-10-31 Astrazeneca Ab Kemične spojine
BRPI0608160A2 (pt) 2005-02-16 2010-11-09 Astrazeneca Ab anticorpo isolado, célula hospedeira, método de inibir o crescimento de células psma+, e, uso de um anticorpo anti-psma defucosilado
EP1877057A1 (en) 2005-04-27 2008-01-16 AstraZeneca AB Use of pyrazolyl-pyrimidine derivatives in the treatment of pain
CA2607727A1 (en) 2005-04-28 2006-11-09 Mitsubishi Tanabe Pharma Corporation Cyanopyridine derivative and use thereof as medicine
CN101218229A (zh) 2005-05-05 2008-07-09 阿斯利康(瑞典)有限公司 吡唑基-氨基取代的嘧啶及其在癌症治疗中的应用
EP1899323A2 (en) 2005-05-16 2008-03-19 AstraZeneca AB Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
BRPI0618011A2 (pt) 2005-10-28 2011-08-16 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente
US7572809B2 (en) 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
UY30444A1 (es) 2006-06-30 2008-01-31 Astrazeneca Ab Derivados de pirimidina, procesos para su preparacinn, composiciones farmaccuticos y usos de los mismos.
TW200826937A (en) 2006-11-01 2008-07-01 Astrazeneca Ab New use
TW200823196A (en) 2006-11-01 2008-06-01 Astrazeneca Ab New use

Also Published As

Publication number Publication date
PT1846394E (pt) 2012-01-05
US8835465B2 (en) 2014-09-16
DK2383268T3 (en) 2015-09-14
DK1846394T3 (da) 2012-01-16
ES2375735T3 (es) 2012-03-05
IL184674A (en) 2012-07-31
AR056184A1 (es) 2007-09-26
US8324252B2 (en) 2012-12-04
RS52061B (en) 2012-04-30
AU2006210710A1 (en) 2006-08-10
ES2555063T3 (es) 2015-12-28
CN101155800B (zh) 2012-05-23
PL2383268T3 (pl) 2016-02-29
HRP20110962T1 (hr) 2012-01-31
BRPI0606793A8 (pt) 2018-03-13
UY29360A1 (es) 2006-10-02
SA06270007B1 (ar) 2010-11-22
PT2383268E (pt) 2015-12-21
SI2383268T1 (sl) 2016-02-29
NO341112B1 (no) 2017-08-28
EP2383268B1 (en) 2015-09-02
HUE025671T2 (en) 2016-04-28
NZ561145A (en) 2011-02-25
EP1846394A1 (en) 2007-10-24
MX2007009437A (es) 2007-08-16
ATE530545T1 (de) 2011-11-15
EP2383268A1 (en) 2011-11-02
HK1114374A1 (en) 2008-10-31
TWI370127B (en) 2012-08-11
WO2006082392A1 (en) 2006-08-10
JP5139084B2 (ja) 2013-02-06
HK1163677A1 (zh) 2012-09-14
CN101155800A (zh) 2008-04-02
KR20070107107A (ko) 2007-11-06
NO20073791L (no) 2007-08-30
JP2008528664A (ja) 2008-07-31
PL1846394T3 (pl) 2012-04-30
BRPI0606793A2 (pt) 2009-12-01
CA2595834A1 (en) 2006-08-10
US20130090358A1 (en) 2013-04-11
CA2595834C (en) 2013-04-30
CY1119077T1 (el) 2018-01-10
AU2006210710B2 (en) 2009-12-10
EP1846394B1 (en) 2011-10-26
SI1846394T1 (sl) 2012-06-29
KR101302945B1 (ko) 2013-09-06
MY149512A (en) 2013-09-13
US20080139561A1 (en) 2008-06-12
ME02645B (me) 2012-04-30
IL184674A0 (en) 2007-12-03

Similar Documents

Publication Publication Date Title
CY1115078T1 (el) Παραγωγα πυραζολοαμινοπυριδινης χρησιμα ως αναστολεις της κινασης
DK1853602T3 (da) Kemiske forbindelser
DK1853588T3 (da) Kemiske forbindelser
NO2023022I1 (no) cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate
NO2017019I1 (no) Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav
EA200700225A1 (ru) Аналоги тетрапептида
TW200716606A (en) Chemical compounds
TW200800963A (en) Chemical compounds
EA201070247A1 (ru) Ингибиторы протеасом
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
EA200801428A1 (ru) Производные пиридиазинона для лечения опухолей
CY1113560T1 (el) Αζαϊνδολια χρησιμα ως αναστολεις των jak και αλλων πρωτεϊνικων κινασων
EA200870569A1 (ru) Соединения и способы модуляции fxr
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
EA200801414A1 (ru) Кальцилитические соединения
CY1110891T1 (el) Παραγωγα 6-ετεροαρυλπυριδοϊνδολονης, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη αγωγη
EA200701688A1 (ru) Замещённые пирролы, содержащие их композиции, способ получения и применение
CY1109747T1 (el) Μεθοδος διεργασιων για την παρασκευη αναστολεων τρυπτασης
CY1113832T1 (el) Μεθοδος για την στερεοεκλεκτικη παρασκευη (-)-halofenate και παραγωγων αυτης
CY1116426T1 (el) Ενωσεις διαρυλυδαντοϊνης
CY1113655T1 (el) Παραγωγα 4-(3-αμινοπυραζολο) πυριμιδινης για χρηση ως αναστολεις κινασων τυροσινης στη θεραπευτικη αγωγη καρκινου
CY1114807T1 (el) Ενωσεις 2,4-πυριμιδινοδιαμινης για τη θεραπευτικη αντιμετωπιση ή την προληψη αυτοανοσων νοσων
CY1114511T1 (el) Καρβονυλαμινο πυρρολοπυραζολες, ικανοι αναστολεις κινασων
EA201791835A3 (ru) Ингибиторы протеасом